Amgen (AMGN) Reports Q4 Beat
Tweet
Share
E-mail_58cbc46cd3c33.jpg)
Get Alerts AMGN Hot Sheet
Price: $363.39 -0.06%
EPS Growth %: -7.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -7.1%
Financial Fact:
Total operating expenses: 3.28B
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Amgen (NASDAQ: AMGN) reported its Q4 results, with EPS coming in at $4.36, beating the consensus estimate of $4.12. Revenue grew 3% year-over-year to $6.85 billion, slightly missing the consensus estimate of $6.88 billion, driven by increased Other Revenue from the Eli Lilly and Company COVID-19 manufacturing collaboration.
Total product sales for Q4 decreased 1% year-over-year. Unit volumes increased 7% but were more than offset by lower net selling price and lower inventory levels.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) PT Lowered to $333 at Morgan Stanley
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- PepsiCo (PEP) Misses Q2 EPS by 1c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
